Abstract
The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand-1 (PD-L1). The intense interest in drug development in this area has resulted in additional agents with associated diagnostics looming on the horizon in 2016. In the era of precision medicine, the paradigm of paired molecular target and molecular test, which serves as a model of oncogenic mutation-driven cancer therapy, is challenged by the proliferation of immunohistochemistry-based tests with different antibodies, instruments, and scoring. The difficulty inherent to targeted therapy aimed at a moving target is discussed, as well as the emerging challenges to pathologists and oncologists who seek to optimize care in this complex therapeutic arena.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 351-354 |
| Number of pages | 4 |
| Journal | Archives of Pathology and Laboratory Medicine |
| Volume | 140 |
| Issue number | 4 |
| DOIs | |
| State | Published - Apr 1 2016 |
Fingerprint
ASJC Scopus subject areas
- Pathology and Forensic Medicine
- Medical Laboratory Technology
Cite this
PD-L1 and lung cancer : The era of precision-ish medicine? / Borczuk, Alain C.; Allen, Timothy Craig.
In: Archives of Pathology and Laboratory Medicine, Vol. 140, No. 4, 01.04.2016, p. 351-354.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - PD-L1 and lung cancer
T2 - The era of precision-ish medicine?
AU - Borczuk, Alain C.
AU - Allen, Timothy Craig
PY - 2016/4/1
Y1 - 2016/4/1
N2 - The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand-1 (PD-L1). The intense interest in drug development in this area has resulted in additional agents with associated diagnostics looming on the horizon in 2016. In the era of precision medicine, the paradigm of paired molecular target and molecular test, which serves as a model of oncogenic mutation-driven cancer therapy, is challenged by the proliferation of immunohistochemistry-based tests with different antibodies, instruments, and scoring. The difficulty inherent to targeted therapy aimed at a moving target is discussed, as well as the emerging challenges to pathologists and oncologists who seek to optimize care in this complex therapeutic arena.
AB - The success of immune checkpoint inhibitor therapy in lung cancer, both in squamous and nonsquamous non-small cell carcinoma, has led to US Food and Drug Administration approval for 2 medications that have as part of their prescribing information an associated immunohistochemistry-based companion or complementary diagnostic test for programmed death ligand-1 (PD-L1). The intense interest in drug development in this area has resulted in additional agents with associated diagnostics looming on the horizon in 2016. In the era of precision medicine, the paradigm of paired molecular target and molecular test, which serves as a model of oncogenic mutation-driven cancer therapy, is challenged by the proliferation of immunohistochemistry-based tests with different antibodies, instruments, and scoring. The difficulty inherent to targeted therapy aimed at a moving target is discussed, as well as the emerging challenges to pathologists and oncologists who seek to optimize care in this complex therapeutic arena.
UR - http://www.scopus.com/inward/record.url?scp=84964088601&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964088601&partnerID=8YFLogxK
U2 - 10.5858/arpa.2015-0509-SA
DO - 10.5858/arpa.2015-0509-SA
M3 - Article
VL - 140
SP - 351
EP - 354
JO - Archives of Pathology and Laboratory Medicine
JF - Archives of Pathology and Laboratory Medicine
SN - 0003-9985
IS - 4
ER -